Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: neurogenesis therapeutics - Newron Sweden

Next Previous
Drug Profile

Research programme: neurogenesis therapeutics - Newron Sweden

Alternative Names: sNN 0126; sNN 0465

Latest Information Update: 13 Sep 2013

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroNova AB
  • Developer Newron Sweden AB
  • Class Nerve growth factors; Peptides; Proteins; Small molecules
  • Mechanism of Action Neuron stimulants; Neuropilin-1 inhibitors; Platelet-derived growth factor receptor agonists; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Amyotrophic lateral sclerosis; Huntington's disease; Major depressive disorder; Neurological disorders; Parkinson's disease

Most Recent Events

  • 13 Sep 2013 Discontinued - Preclinical for Alzheimer's disease in Sweden (unspecified route)
  • 13 Sep 2013 Discontinued - Preclinical for Amyotrophic lateral sclerosis in Sweden (Intracerebro-ventricular)
  • 13 Sep 2013 Discontinued - Preclinical for Huntington's disease in Sweden (unspecified route)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top